ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Hydrochloric Acid → 1-{2-[3-(5-{3-Chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2-(methyloxy)phenyl]ethyl}-4-piperidinecarboxylic acid

HRID 1942755
ノート
印刷プレビュー

反応式

HRID 1942755 の反応式
[Cl:1][C:2]1[CH:3]=[C:4]([C:12]2[S:16][N:15]=[C:14]([C:17]3[C:18]([O:36][CH3:37])=[C:19]([CH2:23][CH2:24][N:25]4[CH2:30][CH2:29][CH:28]([C:31]([O:33]CC)=[O:32])[CH2:27][CH2:26]4)[CH:20]=[CH:21][CH:22]=3)[N:13]=2)[CH:5]=[CH:6][C:7]=1[O:8][CH:9]([CH3:11])[CH3:10].[OH-].[Na+].Cl>O1CCCC1.C(O)C.O>[Cl:1][C:2]1[CH:3]=[C:4]([C:12]2[S:16][N:15]=[C:14]([C:17]3[C:18]([O:36][CH3:37])=[C:19]([CH2:23][CH2:24][N:25]4[CH2:26][CH2:27][CH:28]([C:31]([OH:33])=[O:32])[CH2:29][CH2:30]4)[CH:20]=[CH:21][CH:22]=3)[N:13]=2)[CH:5]=[CH:6][C:7]=1[O:8][CH:9]([CH3:10])[CH3:11]
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 3

HCID 313Hydrochloric AcidHCID 14798Sodium Hydroxide2 回HCID 58494139Ethyl 1-{2-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2-(methyloxy)phenyl]ethyl}-4-piperidinecarboxylate

生成物 1

HCID 545784611-{2-[3-(5-{3-Chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2-(methyloxy)phenyl]ethyl}-4-piperidinecarboxylic acid収率 27.3%

試薬・触媒・溶媒 3

HCID 702
Ethanol
溶媒
HCID 962Water溶媒
HCID 8028Tetrahydrofuran溶媒

実験手順

To a solution of ethyl 1-{2-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2-(methyloxy)phenyl]ethyl}-4-piperidinecarboxylate (D104) (38.7 mg, 0.071 mmol) in Tetrahydrofuran (THF) (10 mL), Ethanol (2 mL) and Water (1 mL) was added sodium hydroxide (56.9 mg, 1.423 mmol). The reaction mixture was stirred at room temperature overnight (16 h). Sodium hydroxide (56.9 mg, 1.423 mmol) was added again. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was acidified with 2N HCl solution till pH ˜6.0. The organic solvent was removed. Then the mixture was extracted with EA/THF. The combined organic layers were concentrated. The residue was re-dissolved in THF/water and then purified by Mass Directed AutoPrep to afford 1-{2-[3-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-thiadiazol-3-yl)-2-(methyloxy)phenyl]ethyl}-4-piperidinecarboxylic acid (E73) (10 mg) as a TFA salt. δH (DMSO-d6, 400 MHz): 1.35 (6H, d), 1.78 (2H, m), 1.94 (1H, m), 2.12 (2H, d), 2.55 (1H, m), 3.08 (4H, m), 3.29 (3H, m), 3.49 (3H, m), 3.66 (2H, d), 4.87 (1H, dt), 7.29 (1H, t), 7.40 (1H, d), 7.49 (1H, m), 7.93 (1H, m), 8.04 (1H, dd), 8.16 (1H, d), 9.51 (1H, br. s.), 12.59 (1H, br. s.). δF (DMSO-d6, 376 MHz): −73.5. MS (ES): C28H34ClN3O3S requires 515.2. found 516.2 (M+H+).

後処理

  1. stirringThe reaction mixture was stirred at room temperature for 4 hours
  2. customThe organic solvent was removed
  3. extractionThen the mixture was extracted with EA/THF
  4. concentrationThe combined organic layers were concentrated
  5. dissolutionThe residue was re-dissolved in THF/water
  6. custompurified by Mass Directed AutoPrep

出典と根拠

ORDレコード
ord-9f99957349ef4f8eb6481dcaf9daf5fc
出典データセット
uspto-grants-2013_03
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08389508B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート